一例慢性中性粒细胞白血病合并多发性骨髓瘤病例显示来那度胺和环磷酰胺联合治疗对这两种疾病均有益处。 - Suppr

Suppr

超能文献

A case of chronic neutrophilic leukemia and multiple myeloma showing the benefits of lenalidomide and cyclophosphamide therapy in treating both conditions.

作者信息

McVinnie Kathryn, Innes Andrew, Nadal-Melsio Elisabet, Atta Maria, Deplano Simona

机构信息

Department of Haematology, Hammersmith Hospital, London, UK.

Department of Molecular Pathology, Hammersmith Hospital, London, UK.

出版信息

Am J Hematol. 2022 Nov;97(11):1491-1494. doi: 10.1002/ajh.26670. Epub 2022 Sep 10.

DOI:10.1002/ajh.26670

PMID:35898175

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9825857/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e3a/9825857/b9d9a4300710/AJH-97-1491-g003.jpg

相似文献

A case of chronic neutrophilic leukemia and multiple myeloma showing the benefits of lenalidomide and cyclophosphamide therapy in treating both conditions.

Am J Hematol. 2022 Nov;97(11):1491-1494. doi: 10.1002/ajh.26670. Epub 2022 Sep 10.

Successful outcome of anaplastic multiple myeloma with lenalidomide, cyclophosphamide, and dexamethasone therapy.

Ann Hematol. 2021 Dec;100(12):3039-3040. doi: 10.1007/s00277-020-04244-7. Epub 2020 Sep 2.

Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study.

Clin Lymphoma Myeloma Leuk. 2020 Feb;20(2):e97-e104. doi: 10.1016/j.clml.2019.10.017. Epub 2019 Oct 31.

Assessing Pretransplant and Posttransplant Therapy Response in Multiple Myeloma Patients.

Curr Oncol. 2022 Nov 8;29(11):8501-8512. doi: 10.3390/curroncol29110670.

Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial.

Am J Hematol. 2011 Aug;86(8):640-5. doi: 10.1002/ajh.22053. Epub 2011 May 31.

Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse.

Br J Haematol. 2020 Mar;188(6):907-917. doi: 10.1111/bjh.16287. Epub 2020 Jan 2.

Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.

Lancet Oncol. 2015 Dec;16(16):1617-29. doi: 10.1016/S1470-2045(15)00389-7. Epub 2015 Nov 17.

Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.

Lancet Haematol. 2021 Nov;8(11):e794-e807. doi: 10.1016/S2352-3026(21)00208-8. Epub 2021 Sep 13.

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.

Blood. 2008 Dec 1;112(12):4445-51. doi: 10.1182/blood-2008-02-141614. Epub 2008 Sep 17.

Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial.

Blood Cancer J. 2019 Apr 8;9(4):45. doi: 10.1038/s41408-019-0206-8.

引用本文的文献

Chronic Neutrophilic Leukemia: Advances in Diagnosis, Genetic Insights, and Management Strategies.

Cancers (Basel). 2025 Jan 12;17(2):227. doi: 10.3390/cancers17020227.

本文引用的文献

Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission.

Cancer. 2021 Jun 1;127(11):1894-1900. doi: 10.1002/cncr.33409. Epub 2021 Jan 15.

Chronic neutrophilic leukemia: 2018 update on diagnosis, molecular genetics and management.

Am J Hematol. 2018 Aug;93(4):578-587. doi: 10.1002/ajh.24983.

Genomics of chronic neutrophilic leukemia.

Blood. 2017 Feb 9;129(6):715-722. doi: 10.1182/blood-2016-10-695981. Epub 2016 Dec 27.

A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes.

Nat Med. 2016 Jul;22(7):727-34. doi: 10.1038/nm.4127. Epub 2016 Jun 13.

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11.

Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.

Lancet Haematol. 2015 Jan;2(1):e12-20. doi: 10.1016/S2352-3026(14)00026-X. Epub 2014 Dec 22.

Chronic neutrophilic leukaemia and plasma cell-related neutrophilic leukaemoid reactions.

Br J Haematol. 2015 Nov;171(3):400-10. doi: 10.1111/bjh.13600. Epub 2015 Jul 27.

Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.

Blood. 2014 Jul 24;124(4):536-45. doi: 10.1182/blood-2014-02-557819. Epub 2014 Jun 9.

Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.

Science. 2014 Jan 17;343(6168):301-5. doi: 10.1126/science.1244851. Epub 2013 Nov 29.

Severe congenital neutropenia and chronic neutrophilic leukemia: an intriguing molecular connection unveiled by oncogenic mutations in CSF3R.

Haematologica. 2013 Oct;98(10):1490-2. doi: 10.3324/haematol.2013.090571.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

A case of chronic neutrophilic leukemia and multiple myeloma showing the benefits of lenalidomide and cyclophosphamide therapy in treating both conditions.

作者信息

McVinnie Kathryn, Innes Andrew, Nadal-Melsio Elisabet, Atta Maria, Deplano Simona

机构信息

Department of Haematology, Hammersmith Hospital, London, UK.

Department of Molecular Pathology, Hammersmith Hospital, London, UK.

出版信息

Am J Hematol. 2022 Nov;97(11):1491-1494. doi: 10.1002/ajh.26670. Epub 2022 Sep 10.

DOI:10.1002/ajh.26670

PMID:35898175

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9825857/

Abstract

摘要

相似文献

A case of chronic neutrophilic leukemia and multiple myeloma showing the benefits of lenalidomide and cyclophosphamide therapy in treating both conditions.

Am J Hematol. 2022 Nov;97(11):1491-1494. doi: 10.1002/ajh.26670. Epub 2022 Sep 10.

Successful outcome of anaplastic multiple myeloma with lenalidomide, cyclophosphamide, and dexamethasone therapy.

Ann Hematol. 2021 Dec;100(12):3039-3040. doi: 10.1007/s00277-020-04244-7. Epub 2020 Sep 2.

Clin Lymphoma Myeloma Leuk. 2020 Feb;20(2):e97-e104. doi: 10.1016/j.clml.2019.10.017. Epub 2019 Oct 31.

Assessing Pretransplant and Posttransplant Therapy Response in Multiple Myeloma Patients.

Curr Oncol. 2022 Nov 8;29(11):8501-8512. doi: 10.3390/curroncol29110670.

Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial.

Am J Hematol. 2011 Aug;86(8):640-5. doi: 10.1002/ajh.22053. Epub 2011 May 31.

Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse.

Br J Haematol. 2020 Mar;188(6):907-917. doi: 10.1111/bjh.16287. Epub 2020 Jan 2.

Lancet Oncol. 2015 Dec;16(16):1617-29. doi: 10.1016/S1470-2045(15)00389-7. Epub 2015 Nov 17.

Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.

Lancet Haematol. 2021 Nov;8(11):e794-e807. doi: 10.1016/S2352-3026(21)00208-8. Epub 2021 Sep 13.

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.

Blood. 2008 Dec 1;112(12):4445-51. doi: 10.1182/blood-2008-02-141614. Epub 2008 Sep 17.

Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial.

Blood Cancer J. 2019 Apr 8;9(4):45. doi: 10.1038/s41408-019-0206-8.

引用本文的文献

Chronic Neutrophilic Leukemia: Advances in Diagnosis, Genetic Insights, and Management Strategies.

Cancers (Basel). 2025 Jan 12;17(2):227. doi: 10.3390/cancers17020227.

本文引用的文献

Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission.

Cancer. 2021 Jun 1;127(11):1894-1900. doi: 10.1002/cncr.33409. Epub 2021 Jan 15.

Chronic neutrophilic leukemia: 2018 update on diagnosis, molecular genetics and management.

Am J Hematol. 2018 Aug;93(4):578-587. doi: 10.1002/ajh.24983.

Genomics of chronic neutrophilic leukemia.

Blood. 2017 Feb 9;129(6):715-722. doi: 10.1182/blood-2016-10-695981. Epub 2016 Dec 27.

A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes.

Nat Med. 2016 Jul;22(7):727-34. doi: 10.1038/nm.4127. Epub 2016 Jun 13.

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11.

Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.

Lancet Haematol. 2015 Jan;2(1):e12-20. doi: 10.1016/S2352-3026(14)00026-X. Epub 2014 Dec 22.

Chronic neutrophilic leukaemia and plasma cell-related neutrophilic leukaemoid reactions.

Br J Haematol. 2015 Nov;171(3):400-10. doi: 10.1111/bjh.13600. Epub 2015 Jul 27.

Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.

Blood. 2014 Jul 24;124(4):536-45. doi: 10.1182/blood-2014-02-557819. Epub 2014 Jun 9.

Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.

Science. 2014 Jan 17;343(6168):301-5. doi: 10.1126/science.1244851. Epub 2013 Nov 29.

Severe congenital neutropenia and chronic neutrophilic leukemia: an intriguing molecular connection unveiled by oncogenic mutations in CSF3R.

Haematologica. 2013 Oct;98(10):1490-2. doi: 10.3324/haematol.2013.090571.